Save
Share
Ibrutinib plus venetoclax improves progression-free survival in refractory or relapsed mantle cell lymphoma.
Journal:
Cancer
Published:
June 17, 2025
Authors
Mary Nierengarten
Relevant Conditions
Non-Hodgkin Lymphoma
,
Mantle Cell Lymphoma (MCL)
View Article From Source
Similar Publications
We couldn’t find any related articles. Please check for more on the main search page.